Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 3,757 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Respiratory Disease, Acute Respiratory Infection, Respiratory Infection, Upper Respiratory Infection
Interventions: Online Tutorial, Webinars, Booster Sessions, Feedback Reports, Parent Survey; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Months to 10 Years
Enrollment: 2,728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 20
States / cities: Paragould, Arkansas • Eureka, California • Durango, Colorado + 16 more

Conditions: Carcinoma, Squamous Cell, Anorectal Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation; Biological · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Phenylketonuria, PKU
Interventions: RDD to Palynziq; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Solid Tumors, Adult
Interventions: HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose; Drug
Lead sponsor: HighField Biopharmaceuticals Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Substance-related Disorders
Interventions: Implementation Facilitation; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 3,838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Hartford, Connecticut • New Haven, Connecticut • Brooklyn, New York + 1 more

Conditions: Solid Tumors, Central Nervous System Tumors
Interventions: Vinblastine and Sirolimus; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: Up to 21 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: San Diego, California • St Louis, Missouri • Burlington, Vermont

Conditions: Moyamoya Syndrome, Moyamoya Disease, Atheroscleroses, Cerebral
Interventions: Soterix® 4x1HD-TDCS, Soterix® 1x1 tDCS, Cognitive training program; Device · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autism Spectrum Disorder
Interventions: Engagement Intervention, Engagement + Coaching Intervention; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 12 Months to 24 Months
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Coral Gables, Florida • Tallahassee, Florida • Boston, Massachusetts

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Ribociclib, T-DM1, Trastuzumab, Fulvestrant; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer Pain
Interventions: Individual patient interview, focus group and structured survey, interview, focus group and structured survey; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lung Cancer
Interventions: reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 10
States / cities: Iowa City, Iowa • Baltimore, Maryland • Minneapolis, Minnesota + 6 more

Conditions: Non Hodgkin Lymphoma
Interventions: 64Cu-GRIP B, Positron Emission Tomography (PET), Optional tumor biopsy; Drug · Procedure
Lead sponsor: Michael Randall; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Leukemia
Interventions: Oxaliplatin, Fludarabine, Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions: EB-101; Biological
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 6 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Redwood City, California • Worcester, Massachusetts

Conditions: Phenylketonurias, PAH Deficiency, Phenylketonuria
Interventions: HMI-103; Drug
Lead sponsor: Homology Medicines, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Topeka, Indiana • Lancaster, Pennsylvania

Conditions: Advanced Non-Small Cell Lung Cancer With MET Mutations
Interventions: Tepotinib; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Sacramento, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more

Conditions: HIV Infections
Interventions: VH4524184, Midazolam, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Health Behavior, Health Care Utilization
Interventions: Phase II Promotores de Salud, Phase I Promotores de Salud Outreach; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 3 Years and older
Enrollment: 1,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Kidney Cancer
Interventions: IL-2, ATRA; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cancer
Interventions: cyclophosphamide, Cryoablation; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tesevatinib; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more

Conditions: Heart Failure
Interventions: Mobile phone app (VAD Care App), Usual LVAD Care; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: St Louis, Missouri • Lincoln, Nebraska • New York, New York

Search by objective public record fields.

Dialogue Around Respiratory Illness Treatment

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours

A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion

Autism Adaptive Community-based Treatment to Improve Outcomes Using Navigators (ACTION) Network

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol

Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Self-Management App for Patients With Left-Ventricular Assist Devices